We further investigated the role of the different PPAR isotypes (and their therapeutic potential) on the structural and functional aspects of the altered hepatic vascular biology, including LSEC changes, in two animal models of early MASLD, with the aim to understand the role of these vascular changes in disease progression. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.